Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,141 MXN
Change Today +135.70 / 13.50%
Volume 5.2K
As of 4:09 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Open
$1,126
Previous Close
$1,005
Day High
$1,141
Day Low
$1,126
52 Week High
07/27/15 - $1,141
52 Week Low
09/9/14 - $677.00
Market Cap
967.4B
Average Volume 10 Days
1.5K
EPS TTM
--
Shares Outstanding
848.0M
EX-Date
05/15/15
P/E TM
--
Dividend
$1.26
Dividend Yield
1.67%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVAN)

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Reportedly In Talks To Buy Allergan Big Generic-Drug Unit

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reportedly is in talks to combine with Allergan plc (NYSE:AGN)'s big generic-drug business, people familiar with the matter said. A deal for the Allergan business, valued at about $45 billion, could be announced as early as July27, 2015, one of the people said. The Allergan unit would be spun off and combined with Teva, which has a market value of $60 billion, this person told the newspaper. Terms of the Teva deal are still being worked out, including whether Allergan’s drug-distribution business will be a part of deal, according to one of the people familiar with the talks. A spokesman for Allergan, Alex Kelly, declined to comment.

Teva Pharmaceutical Industries Ltd. Launches Migraine Drug in US

Teva Pharmaceutical Industries Ltd. launched generic Axert or almotriptan malate, tablets, 6.25 mg and 12.5 mg, for the treatment of acute migraine, in the US. Teva was the first applicant to submit an Abbreviated New Drug Application (ANDA) for almotriptan malate tablets containing a Paragraph IV patent certification. The ANDA for almotriptan malate tablets submitted by Teva to the FDA on December 7, 2005, was the first ANDA submitted by a generic company containing a Paragraph IV certification for Janssen Pharmaceuticals Axert. Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.

Teva Pharmaceutical Industries Ltd. Receives Approval and Launch Generic Axert Tablets in the United States

Teva Pharmaceutical Industries Ltd. announced the launch of generic Axert (almotriptan malate) tablets, 6.25 mg and 12.5 mg, in the United States. The company was the first applicant to submit an Abbreviated New Drug Application (ANDA) for almotriptan malate tablets containing a Paragraph IV patent certification.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $1,140.84 MXN +135.70

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.36
AbbVie Inc $69.34 USD +1.26
AstraZeneca PLC 4,191 GBp -63.00
Eli Lilly & Co $84.15 USD -0.57
Medtronic PLC $75.66 USD -0.35
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings 19.3x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.5x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.